natural pharmaceuticals derived From Cannabis and other medicinal plants

Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product



Namaste Acquires Australian Vaporizers and Increases Bought Deal to $7.5M

  • Entered into a definitive agreement with Australian Vaporizers PTY Limited
  • Company’s website has approximately 80% of the market share
  • For period ended June 30, 2016, the company produced approximately $4.5 million of revenue and $1.1 million of EBITDA


Hub On AGORACOM / Read Release


Durango Receives Offers On Windfall Gold Camp Property


Last: $0.18 Up: $0.115

Vol. 21.5M Shares

  • Received two offers this week on its Trove Property located in the Windfall Lake
  • 100% wholly owned Trove Property adjoins Osisko Mining (TSX-OSK) in the Windfall-Urban gold camp where Osisko is drilling a 400,000 metre program
  • Trove also adjoins Beaufield Resources (TSX.V-BFD) which holds multiple projects in the area and currently have drill programs underway 



Hub On AGORACOM / Read Release

Message: Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials

Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials

posted on Dec 06, 2016 08:30AM

OTTAWA, ONTARIO--(Dec. 6, 2016) - Tetra Bio-Pharma Inc. ("Tetra Bio" or "the Company") (CSE:TBP)(CSE:TBP.CN) and (OTC PINK:GRPOF) is conducting a non-brokered private placement with Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share of the Company at a price of $0.26 per share for a period of 3 years following the closing date. The warrants are subject to an accelerated expiry if the Company's shares trade above $0.45 for thirty (30) consecutive trading days then the warrants will expire in 30 days if not exercised.

The private placement closed on December 5, 2016.

Completion of the private placement is subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date.

The proceeds of the private placement will be used to initiate clinical trials in PhytoPain Pharma Inc.

"Obtaining an investment from one of Canada's leading cannabis producers re-enforces the value of the research and development being conducted by the science team at Tetra Bio-Pharma lead by Chief Science Officer, Dr. Guy Chamberland," commented Ryan Brown, Co-Founder/VP Business Development.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402

New Message
Please login to post a reply